Novavax, Inc. (NASDAQ:NVAX) recently shared, that Stanley Erck has been appointed to the board's corporate governance, compensation and finance committees, replacing board chairman John Lambert on the finance committee and board member James Tananbaum who is retiring from the board. Mr. Erck has previously served as CEO of several vaccine and immunology products companies and joined the Novavax (NASDAQ:NVAX) board in June 2009.
Free Hot Penny Stocks, an online financial publication, provides investors timely stock market alerts. Free hot penny stocks profiles stock picks that could generate higher returns than average. These penny stocks include stocks with news, chart breakouts or increased volume.
Sign Up Today for our Penny Stock Newsletter
John Lambert stated: "Our board's membership and responsibilities are continuing to evolve as Novavax (NASDAQ:NVAX) matures as an operating company and advances its vaccine candidates toward commercialization. We thank Jim for his three and a half years of service to our company and appreciate Stan's willingness to take on additional responsibilities which reflect his experience in vaccine development and the biopharmaceutical industry." Dr. Tananbaum commented: "I have greatly enjoyed my affiliation with Novavax (NASDAQ:NVAX) and am impressed with the company's recent progress. VLP technology is proving to be a valuable platform for vaccine development and I wish the team continued success in the years ahead." Novavax is a clinical-stage biotechnology company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces these VLP-based, potent, recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is a clinical-stage biotechnology company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. Novavax produces these VLP based, potent, recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is focused on creating novel, highly potent recombinant vaccines produced via cell culture. The company has developed three proprietary technology platforms–Virus-Like Particles and Novasome paucilamellar vesicles. “Our vision is a holistic approach to controlling the spread of disease. Using a unique portable manufacturing system that allows for raped mass production, our long term goal is to be able to rapidly deliver a customized vaccine in the midst of a pandemic.”
Sign Up for Free Hot Penny Stocks’ FREE Penny Stock Newsletter.
About Us
Free Hot Penny Stocks is a financial website and independent electronic publication that provides information and free penny stock alerts on selected publicly traded companies. We also track small cap companies and other stocks that may be positioned to break out. These penny stocks might have news, increased volume or chart breakouts. These penny stocks that are alerted could generate greater than average returns. Feel free to visit our penny stock forum to discuss other penny stock picks or penny stocks that you might own.
Free Hot Penny Stocks is not a registered investment advisor or broker-dealer. Please do your own Due Diligence before investing in any of the stocks mentioned above. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
